&w=3840&q=100)
Dr explains: How air pollution, stress and late pregnancies are fuelling India's fertility crisis
Infertility is emerging as a pressing public health concern in India, affecting an estimated 10–15% of couples according to studies published in The Lancet and other medical journals. The issue has been further spotlighted by government data and clinical observations pointing to a surge in conditions like PCOS, endometriosis and declining sperm quality, particularly in urban centres.
Environmental stressors such as air pollution and exposure to endocrine-disrupting chemicals, combined with sedentary lifestyles and delayed family planning, are compounding the crisis. The Indian Council of Medical Research and the Ministry of Health have taken regulatory steps with the Assisted Reproductive Technology (Regulation) Act to ensure standardised fertility care but challenges around accessibility, affordability and awareness persist—especially in tier-2 and tier-3 cities.
STORY CONTINUES BELOW THIS AD
Firstpost talked to Dr. Mannan Gupta, Chairman & HOD, Obstetrics & Gynaecology & IVF, Elantis Healthcare (New Delhi) to understand the underlying medical and environmental factors behind India's infertility burden, how air pollution and lifestyle are affecting IVF outcomes, and the current state of ART practices across the country.
What are the main medical and environmental factors behind the rising burden of infertility in India?
Dr Mannan: Infertility now affects nearly 10–15% of couples in India, and the trend is steadily increasing. Medically, rising cases of Polycystic Ovary Syndrome (PCOS), endometriosis, thyroid disorders, diabetes, and obesity in women are significant contributors. In men, conditions like varicocele, hormonal imbalances, and poor sperm parameters are commonly seen. Environmentally, increasing exposure to endocrine-disrupting chemicals (EDCs), air pollution, and unhealthy lifestyle habits—such as poor diet, lack of exercise, smoking, alcohol consumption, and chronic stress—are worsening reproductive health. Additionally, delayed marriages and late pregnancy planning have become major socio-cultural factors contributing to declining fertility.
How are declining sperm quality and ovarian reserve due to air pollution and sedentary lifestyles impacting IVF outcomes, especially in urban India?
Dr Mannan: In urban settings, declining sperm counts and ovarian reserves have become major challenges for successful conception—both naturally and via assisted reproduction. Studies show increasing DNA fragmentation in sperm and diminished anti-Müllerian hormone (AMH) levels in women exposed to high-pollution environments. These directly reduce embryo quality and negatively impact IVF success rates. Sedentary habits, obesity, and poor sleep hygiene further impair hormonal health. As a result, we often require multiple IVF cycles and personalised stimulation protocols to achieve a viable pregnancy, especially in metropolitan cities.
How accessible and affordable is IVF treatment across India, particularly in tier-2 and tier-3 cities?
Dr Mannan: While IVF is gaining popularity and acceptance, affordability and access remain significant hurdles outside metro cities. In tier-2 and tier-3 areas, there is limited availability of advanced infrastructure, skilled embryologists, and fertility specialists. Many couples are forced to travel to metro cities, which increases emotional and financial burdens. Moreover, infertility is still considered taboo in several regions, leading to delayed medical intervention. Although some states are considering subsidised treatment or insurance coverage for infertility, there is still a long way to go in terms of accessibility and affordability at the national level.
STORY CONTINUES BELOW THIS AD
What realistic expectations should couples, especially those over 35, have when starting IVF?
Dr Mannan: IVF success rates typically range from 30% to 50%, depending on factors like the woman's age, the cause of infertility, and the clinic's expertise. For women above 35, success rates start to decline due to reduced ovarian reserve and egg quality. It is crucial for couples to understand that IVF is not a guarantee of pregnancy in the first cycle. It may require two or more attempts, and in some cases, advanced techniques like donor eggs or preimplantation genetic testing (PGT) may be recommended. Emotional and psychological support also plays a big role during this journey.
Since the implementation of ICMR guidelines and ART legislation, how have clinical practices, patient safety, and ethical standards changed?
Dr Mannan: The Assisted Reproductive Technology (Regulation) Act and ICMR guidelines have brought much-needed standardisation to IVF practices across India. Clinics now require mandatory registration, ensuring quality control and accountability. There are clear protocols for consent, gamete donation, surrogacy, and embryo storage. This has significantly improved patient safety, reduced unethical practices, and built greater transparency in treatment. While compliance can sometimes increase operational costs, it ultimately enhances trust between patients and healthcare providers.
STORY CONTINUES BELOW THIS AD
Are clinics in India adopting single embryo transfer more frequently to minimise complications from multiple pregnancies?
Dr Mannan: Yes, there is a growing shift towards single embryo transfer (SET), especially in younger women with good-quality embryos. While earlier practices often involved transferring two or more embryos to boost chances, we now understand that multiple pregnancies increase maternal risks such as hypertension, preterm birth, and NICU admissions. With improved embryo culture systems, blastocyst transfers, and technologies like vitrification (rapid freezing), SET has become a safe and effective option. However, adoption still varies across clinics and regions based on patient preference, cost considerations, and expectations.
What does current evidence suggest about egg freezing and fertility preservation in working women and cancer patients?
Dr Mannan: Egg freezing has emerged as a valuable tool for fertility preservation. For working women who wish to delay childbearing, freezing eggs before the age of 35 offers the best chance of future success. In cancer patients, fertility preservation before undergoing chemotherapy or radiotherapy is becoming standard practice. Evidence shows that frozen eggs, when used within 5–10 years, can lead to pregnancy rates comparable to fresh eggs—provided they were retrieved at an optimal age and under proper protocols. The key is early counselling and timely decision-making.
STORY CONTINUES BELOW THIS AD
How widely are advanced technologies like AI and time-lapse imaging being adopted in Indian IVF clinics, and do they improve outcomes?
Dr Mannan: Advanced technologies such as AI-based embryo selection and time-lapse imaging (like EmbryoScope) are being increasingly integrated into top-tier IVF centres in India. These tools offer real-time monitoring of embryo development and help identify embryos with the best implantation potential. AI algorithms analyse thousands of data points to assist embryologists in decision-making. While the evidence is promising—especially in reducing subjectivity and improving selection accuracy—more long-term data is needed to confirm significant improvements in live birth rates. Cost is another limiting factor, making these technologies less accessible in smaller cities.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
2 hours ago
- Time of India
ICT Mumbai biocluster receives catalytic funding to boost translational biopharma research
Mumbai: In a significant boost to India's translational research ecosystem, ICT Mumbai's Biocluster secured Rs 30 crore in catalytic funding from the Indian Translational Research Institute (ITRI). The translational biopharmaceutical facility aims to bridge the gap between lab-stage research and clinical application. The eight-storey cluster will focus on rare diseases, synthetic biology, and AI-driven drug development. It will house a GMP-ready biologics pilot plant, shared R&D infrastructure, and advanced training zones for workforce development. Dr Ratnesh Jain, Principal Investigator of the project, said the Biocluster aims to make Indian biopharma globally competitive. ITRI CEO Dr Abdur Rub emphasised the need to de-risk innovation and scale healthcare solutions. Positioned as a national translational platform, the Mumbai Biocluster seeks to empower startups, academia, and industry alike—enabling faster, capital-efficient transitions from research to real-world impact. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai


Time of India
2 hours ago
- Time of India
Ayurvedic doctor shares what a proper healthy day looks like and what should NOT be done
Let's be honest, life's hectic these days. Most of us barely stop to breathe, let alone think about our daily routines. But funny enough, it's often the small, steady habits that keep us sane. Ayurveda! The old Indian system of health has a few ideas about how to live better. And no, it's not just about herbs and oils. A lot of it is about timing up your daily life with the body's own natural rhythm. They've got a word for it: Dinacharya . It basically means 'daily routine'. Nothing too wild. Just doing things at the right time. Sounds obvious, but it's easy to forget. Starting with the mornings. There's this window, from like 3 AM to 7:30 AM, that's supposed to be ideal for getting up and going. Apparently the first half is ruled by something called Vata, which makes it easier to wake up with a clear head. Once the sun's up, Kapha kicks in, and that's when things feel heavier. So, getting out of bed earlier kind of gives you a head start. What do you do after waking? Well, scrape your tongue, swish a bit of oil around your mouth (oil pulling, they call it), and drink some copper-vessel water if you have one lying around. Sounds odd, but these old tricks are supposed to help get your digestion moving. A bit of stretching or yoga? That's next. Nothing fancy. Maybe 10–15 minutes tops. Throw in some deep breathing or sit quietly. Keeps the stress down and helps your body do its thing. Hormones stay balanced. People feel better. Image : Canva Breakfast? Keep it simple. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Remember Him? Take A Deep Breath Before You See Him Now The Noodle Box Undo Soaked almonds or dates are good. Even some roasted mung bean flour mixed with buttermilk (or lassi) is filling but not heavy. You want fuel, not a food coma. Midday is when your digestion's at its strongest. Around 12 to 1 PM. So, that's when to eat your biggest meal. If you're gonna have something rich or protein-heavy, this is the time. Your body can actually handle it now. By late afternoon, around 3 or 4 PM, you'll probably want a light snack. Nothing big. A piece of fruit or two. Just enough to stop you from crashing. Evenings around 5 to 7 PM is the good time to move. Whether that's a jog, the gym, or just a walk, this is when your muscles are ready to go. After that, slow things down. From 7 PM onwards, you should start switching off. Not saying you need to sit in silence, but maybe ditch the emails. Listen to music. Talk to someone. Do some candle gazing (Trataka), if that's your thing. Light dinner too. Vegetarian's best. Don't eat too late, it messes with your sleep and digestion. Now, this part matters: 10 PM to 2 AM is when your body does the heavy lifting, repairing, restoring, regenerating. If you're still awake scrolling Instagram, you're messing with that process. Try to be asleep by 10. Keep the room dark. Skip the screens. Let your brain and body rest properly. In the end, it's not about being perfect. Ayurveda just gives you a bit of a roadmap. Not a rulebook. Even if you follow a few of these suggestions, wake up earlier, eat when your digestion's strong, sleep on time, you'll likely feel better. (By Dr Somit Kumar, M.D (Ayu), PhD, Chief Scientific Officer & Director of Research, AVP Research Foundation)


Time of India
2 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.